Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous nab-paclitaxel plus Camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells.
Gastric Cancer
DRUG: Camrelizumab Nab-Paclitaxel S-1
R0-resection rate, There was no residual by the microscope, within 3 weeks after surgery|Conversion to negative rate, Exfoliative cytology positive gastric cancer conversion to negative rate, within 3 weeks after surgery
Overall survival (OS), Baseline to measured date of death from any cause, 3years|Progression free survival (PFS), Baseline to measured date of progression or death from any cause, 3years|Objective response rate (ORR), Baseline to measured stable disease, tumor assessment every 6 weeks since the treatment began，up to 3years|Disease control rate (DCR), Baseline to measured progressive disease, tumor assessment every 6 weeks since the treatment began，up to 3years|Tumor regression grade (TRG), TRG included four grades: Grade 0-3, within 3 weeks after surgery|Adverse events, Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The number of Participants with adverse events will be recorded at each treatment visit., 3 years
The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous nab-paclitaxel plus Camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells.